ArticleBMC cancer2018
High CD8
Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Tumour-infiltrating lymphocytes: from prognosis to treatment selection.British journal of cancer · 2023Pooled it
- The effect of immunonutrition on tumor infiltrative t lymphocytes and regulatory t cells in rectal tumor patients receiving neoadjuvant chemoradiotherapy: a prospective randomized clinical study.Turkish journal of medical sciences · 2022Trial
- Spatial Immune Remodeling Across the Gallbladder Carcinogenesis Spectrum: A Multicenter Digital Pathology Study.World journal of oncology · 2026Article
- Molecular convergence in gallbladder cancer: MEK-ERK signalling at the crossroads of oncogenic hubs and pathway cross-talks.Cancer cell international · 2026Review
- CT-based skeletal muscle loss predicts long term prognosis in patients with distal cholangiocarcinoma undergone pancreaticoduodenectomy.Scientific reports · 2025Article
- Review
- Review
- Causal relationship between immune cell phenotypes and risk of biliary tract cancer: evidence from Mendelian randomization analysis.Frontiers in immunology · 2024Article
- CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential.Experimental & molecular medicine · 2023Review
- Increased co-expression of PD1 and TIM3 is associated with poor prognosis and immune microenvironment heterogeneity in gallbladder cancer.Journal of translational medicine · 2023Article
- Cholangiocarcinoma - novel biological insights and therapeutic strategies.Nature reviews. Clinical oncology · 2023Review
- Article
- Immunology and immunotherapy of cholangiocarcinoma.Nature reviews. Gastroenterology & hepatology · 2023Review
- Preclinical evaluation of chimeric antigen receptor T cells targeting the carcinoembryonic antigen as a potential immunotherapy for gallbladder cancer.Oncoimmunology · 2023Article
- Development and validation of a risk prediction score for patients with nasopharyngeal carcinoma.Cancer cell international · 2021Article
- Integrative molecular characterisation of gallbladder cancer reveals micro-environment-associated subtypes.Journal of hepatology · 2021Article
- Review
- Immunohistochemical analysis of the aggregation of CD1a-positive dendritic cells in resected specimens and its association with surgical outcomes for patients with gallbladder cancer.Translational oncology · 2021Article
- Article
- Circulating CEA-dNLR score predicts clinical outcome of metastatic gallbladder cancer patient.Journal of clinical laboratory analysis · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundGallbladder cancer (GBC), although infrequent in industrialized countries, has high incidence rates in certain world regions, being a leading cause of death among elderly Chilean women. Surgery is the only effective treatment, and a five-year survival rate of advanced-stage patients is less than 10%. Hence, exploring immunotherapy is relevant, although GBC immunogenicity is poorly understood. This study examined the relationship between the host immune response and GBC patient survival based on the presence of tumor-infiltrating lymphocytes at different disease stages.
methodsTumor tissues from 80 GBC patients were analyzed by immunohistochemistry for the presence of CD3
resultsThe majority of tumor samples showed CD3
conclusionsDepending on the disease stage, the presence of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.